A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China

CompletedOBSERVATIONAL
Enrollment

181

Participants

Timeline

Start Date

September 8, 2017

Primary Completion Date

August 25, 2020

Study Completion Date

August 25, 2020

Conditions
Psoriasis
Trial Locations (15)

100191

Peking University 3rd Hospital /ID# 213443, Beijing

110003

The 7th People's Hospital of Shenyang /ID# 169829, Shenyang

150086

2nd Aff. Hosp Harbin Med Univ /ID# 169827, Haerbin

200025

Ruijin Hospital, Shanghai Jiaotong /ID# 169833, Shanghai

200072

The Tenth People's Hospital of /ID# 169831, Shanghai

230031

The First Affiliated Hospital /ID# 171398, Hefei

250021

Shandong Provincial Hospital /ID# 169841, Jinan

300381

Jing Tai Tianjin Hospital Co.,Ltd /ID# 208201, Tianjin

310009

The Second Affiliated Hospital /ID# 169842, Hangzhou

310018

Sir Run Run Shaw Hospital /ID# 169834, Jianggan Hangzhou

510018

Dermatology Hospital of southe /ID# 169830, Guangzhou

510030

Guangzhou 1st Muni People Hosp /ID# 208858, Guangzhou

515000

The First Affiliated Hospital of Shantou University Medical College /ID# 209260, Shantou

518110

Shenzhen Hospital of Southern /ID# 169828, Shenzhen

830099

Traditional Chinese Medical Hospital of xinjiang uygur autonomous region /ID# 209183, Ürümqi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY